The role of Far1p in linking the heterotrimeric G protein to polarity establishment proteins during yeast mating

Science

Volumn 282, Issue 5393, 1998, Pages 1511-1516

  Butty, Anne Christine ^a   Pryciak, Peter M ^b   Huang, Linda S ^c   Herskowitz, Ira ^c   Peter, Matthias ^a  

^a SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CELL SURFACE PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHEROMONE;

ARTICLE; CELL CYCLE; CELL POLARITY; CYTOSKELETON; DNA BINDING; MATING; MORPHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION;

SACCHAROMYCES CEREVISIAE;

EID: 0032553474     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.282.5393.1511     Document Type: Article

References (71)

1. J. Chenevert, Mol. Biol. Cell 5, 1169 (1994); D. G. Drubin and W. J. Nelson, Cell 84, 335 (1996); J. Chant, Curr. Opin. Cell Biol. 8, 557 (1996); L. Van Aelst and C. D'Souza-Schorey, Genes Dev. 11, 2295 (1997); A. Hall, Science 279, 509 (1998).
2. J. Chenevert, Mol. Biol. Cell 5, 1169 (1994); D. G. Drubin and W. J. Nelson, Cell 84, 335 (1996); J. Chant, Curr. Opin. Cell Biol. 8, 557 (1996); L. Van Aelst and C. D'Souza-Schorey, Genes Dev. 11, 2295 (1997); A. Hall, Science 279, 509 (1998).
3. J. Chenevert, Mol. Biol. Cell 5, 1169 (1994); D. G. Drubin and W. J. Nelson, Cell 84, 335 (1996); J. Chant, Curr. Opin. Cell Biol. 8, 557 (1996); L. Van Aelst and C. D'Souza-Schorey, Genes Dev. 11, 2295 (1997); A. Hall, Science 279, 509 (1998).
4. J. Chenevert, Mol. Biol. Cell 5, 1169 (1994); D. G. Drubin and W. J. Nelson, Cell 84, 335 (1996); J. Chant, Curr. Opin. Cell Biol. 8, 557 (1996); L. Van Aelst and C. D'Souza-Schorey, Genes Dev. 11, 2295 (1997); A. Hall, Science 279, 509 (1998).
5. J. Chenevert, Mol. Biol. Cell 5, 1169 (1994); D. G. Drubin and W. J. Nelson, Cell 84, 335 (1996); J. Chant, Curr. Opin. Cell Biol. 8, 557 (1996); L. Van Aelst and C. D'Souza-Schorey, Genes Dev. 11, 2295 (1997); A. Hall, Science 279, 509 (1998).
6. I. Herskowitz, Cell 80, 187 (1995); E. Leberer, D. Y. Thomas, M. Whiteway, Curr. Opin. Genet. Dev. 7, 59 (1997); G. F. Sprague and J. W. Thorner, in The Molecular and Cellular Biology of the Yeast Saccharomyces, E. W. Jones, J. R. Pringle, J. R. Broach, Eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1992), p. 657.
7. I. Herskowitz, Cell 80, 187 (1995); E. Leberer, D. Y. Thomas, M. Whiteway, Curr. Opin. Genet. Dev. 7, 59 (1997); G. F. Sprague and J. W. Thorner, in The Molecular and Cellular Biology of the Yeast Saccharomyces, E. W. Jones, J. R. Pringle, J. R. Broach, Eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1992), p. 657.
8. I. Herskowitz, Cell 80, 187 (1995); E. Leberer, D. Y. Thomas, M. Whiteway, Curr. Opin. Genet. Dev. 7, 59 (1997); G. F. Sprague and J. W. Thorner, in The Molecular and Cellular Biology of the Yeast Saccharomyces, E. W. Jones, J. R. Pringle, J. R. Broach, Eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1992), p. 657.
9. H. R. Bourne, Curr. Opin. Cell Biol. 9, 134 (1997); H. E. Hamm, J. Biol. Chem. 273, 669 (1998); D. E. Clapham and E. J. Neer, Annu. Rev. Pharmacol. Toxicol. 37, 167 (1997); H. E. Hamm and A. Gilchrist, Curr. Opin. Cell Biol. 8, 189 (1996).
10. H. R. Bourne, Curr. Opin. Cell Biol. 9, 134 (1997); H. E. Hamm, J. Biol. Chem. 273, 669 (1998); D. E. Clapham and E. J. Neer, Annu. Rev. Pharmacol. Toxicol. 37, 167 (1997); H. E. Hamm and A. Gilchrist, Curr. Opin. Cell Biol. 8, 189 (1996).
11. H. R. Bourne, Curr. Opin. Cell Biol. 9, 134 (1997); H. E. Hamm, J. Biol. Chem. 273, 669 (1998); D. E. Clapham and E. J. Neer, Annu. Rev. Pharmacol. Toxicol. 37, 167 (1997); H. E. Hamm and A. Gilchrist, Curr. Opin. Cell Biol. 8, 189 (1996).
12. H. R. Bourne, Curr. Opin. Cell Biol. 9, 134 (1997); H. E. Hamm, J. Biol. Chem. 273, 669 (1998); D. E. Clapham and E. J. Neer, Annu. Rev. Pharmacol. Toxicol. 37, 167 (1997); H. E. Hamm and A. Gilchrist, Curr. Opin. Cell Biol. 8, 189 (1996).
13. J. E. Segall, Proc. Natl. Acad. Sci. U.S.A. 90, 8332 (1993).
14. J. Chenevert, N. Valtz, I. Herskowitz, Genetics 136, 1287 (1994); N. Valtz, M. Peter, I. Herskowitz, J. Cell Biol. 131, 863 (1995); R. Dorer, P. M. Pryciak, L. H. Hartwell, ibid., p. 845.
15. J. Chenevert, N. Valtz, I. Herskowitz, Genetics 136, 1287 (1994); N. Valtz, M. Peter, I. Herskowitz, J. Cell Biol. 131, 863 (1995); R. Dorer, P. M. Pryciak, L. H. Hartwell, ibid., p. 845.
16. J. Chenevert, N. Valtz, I. Herskowitz, Genetics 136, 1287 (1994); N. Valtz, M. Peter, I. Herskowitz, J. Cell Biol. 131, 863 (1995); R. Dorer, P. M. Pryciak, L. H. Hartwell, ibid., p. 845.
17. A. Nern and R. A. Arkowitz, Nature 391, 195 (1998).
18. K. Schrick, B. Garvik, L. H. Hartwell, Genetics 147, 19 (1997).
19. J. L. Brown, M. Jaquenoud, M. P. Gulli, J. Chant, M. Peter, Genes Dev. 11, 2972 (1997); G. C. Chen, Y. J. Kim, C. S. Chan, ibid., p. 2958.
20. J. L. Brown, M. Jaquenoud, M. P. Gulli, J. Chant, M. Peter, Genes Dev. 11, 2972 (1997); G. C. Chen, Y. J. Kim, C. S. Chan, ibid., p. 2958.
21. B. F. Sloat and J. R. Pringle, Science 200, 1171 (1978); Y. Zheng, R. Cerione, A. Bender, J. Biol. Chem. 269, 2369 (1994).
22. B. F. Sloat and J. R. Pringle, Science 200, 1171 (1978); Y. Zheng, R. Cerione, A. Bender, J. Biol. Chem. 269, 2369 (1994).
23. J. Peterson et al., J. Cell Biol. 127, 1395 (1994).
24. H.-O. Park, E. Bi, J. R. Pringle, I. Herskowitz, Proc. Natl. Acad. Sci. U.S.A. 94, 4463 (1997).
25. T. Leeuw et al., Science 270, 1210 (1995).
26. D. M. Lyons, S. K. Mahanty, K. Y. Choi, M. Manandhar, E. A. Elion, Mol. Cell Biol. 16, 4095 (1996).
27. 2-terminally truncated Cdc24p (amino acids 283 to 853) fused to the LexA DNA-binding domain, was constructed by ligating the genomic 2300-base pair (bp) Eco RI-Bam HI fragment of CDC24 into pEG202. pBTM-CDC24 (2 μm, TRP1, lexA DBD-CDC24) contains full-length, PCR-amplified CDC24 inserted into pBTM116 (36) as a Bam HI-Pst I fragment. The two-hybrid plasmids carrying STE4 were generated by PCR and cloned into pEG202 for the LexA DNA binding domain fusion (pLH163) or pJG4-5 for the B42 transcriptional activation domain fusion (pLH119). pGAD-STE4 (2 μm, LEU2, truncated ADH1 promoter, GAL4 AD-STE4) containing full-length Ste4p in pGAD424 has been described previously [P. M. Pryciak and L. H. Hartwell, Mol. Cell Biol. 16, 2614 (1996)]. pGADXP (2 μm, LEU2, full-length ADH1 promoter, GAL4 AD vector) was constructed by replacing the GAD/polylinker-containing Hind III fragment of pGAD GH (Clontech) with the analogous Hind III fragment from pGAD424 (Clontech); differences in ADH1 promoter length in pGAD424 and pGAD GH result in different expression levels of the AD-fusions. pGADXP-STE4 (2 μm, LEU2, full-length ADH1 promoter, GAL4 AD-STE4) contains full-length, PCR-amplified STE4 inserted into pGADXP as an Eco RI-Bam HI fragment. The two-hybrid plasmids for Bem1p, Gic2p, Cdc42p, Rho1p, and Ste18p have been described previously (8). LexA-fusions to Cdc42p and Rho1p contain the COOH-terminal Cys-to-Ser substitutions to prevent prenylation.
28. 2-terminus, and Akr1p. No significant differences in LacZ reporter activity were detected when two-hybrid assays with Far1p and Bem1p or Cdc24p were performed with cells treated or not treated with a factor.
29. 2-terminus, and Akr1p. No significant differences in LacZ reporter activity were detected when two-hybrid assays with Far1p and Bem1p or Cdc24p were performed with cells treated or not treated with a factor.
30. -6 M was added for 2 hours. Cells were harvested by centrifugation, resuspended in buffer TNE450 [50 mM Tris-HCl (pH 7.5), 450 mM NaCl, 10 mM EDTA, and 0.1% NP-40] and broken with glass beads in a Mini Beadbeater (Biospec). After two sequential centrifugations, the supernatant was incubated for 1 hour with protein G-sepharose beads (Pharmacia) covalently coupled to polyoma antibodies (39). Beads were washed three times with buffer TNE450 and twice with binding buffer [10 mM Tris-HCl (pH 7.5), 85 mM NaCl, 10 mM EDTA, 0.1 % NP-40]. The beads were then divided into aliquots and incubated for 30 min at 4°C with Bem1p-6His purified from E. coli (11). The beads were washed three times with binding buffer and Far1p was then specifically eluted with binding buffer containing 10 μM polyoma peptide (EYMPME) and 0.1% N-octylglucoside (Fluka). Bound Bem1p-6His was detected by immunoblotting using polyclonal antibodies against Bem1p (12).
31. 4 (pH 7.3)]. Bound proteins were eluted with gel-sample buffer and subjected to immunoblot analysis with polyclonal antibodies against Far1p and Cdc24p. Polyclonal antibodies against Cdc24p were raised against a MalE-Cdc24 fusion protein (kindly provided by E. Bi) and affinity purified as described (39). Coimmunoprecipitation experiments with Far1p and Ste4p were carried out as above, except that YMP290 cells were transformed with plasmids expressing Far1p (ACB435) (40) and either epitope-tagged HA-Ste4p (pYEE181) (13) or untagged Ste4p (pTP288) from the inducible GAL promoter. HA11-immunoprecipitates were immunoblotted with polyclonal antibodies against Far1p and Ste4p.
32. Z. S. Zhao, T. Leung, E. Manser, L. Lim, Mol. Cell Biol. 15, 5246 (1995).
33. 1-389). All strains were constructed by single-step gene replacement (37) using the plasmid pTP4 digested with Not I (31); successful replacement of the endogenous FAR1 locus by far1-c was confirmed by the appearance of truncated Far1-c protein by immunoblotting. Mating assays were carried out with the mating tester IH1793 as described (21). In contrast to double mutants between far1-c and proteins functioning in the default mating pathway (such as Pea2p) (5), far1-c cdcZ4-m double mutants mate with an efficiency comparable to each single mutant.
34. 1-389 corresponds to Far1p-c (31). The PCR fragment amplified with the primer pair oTP418/oTP404 digested with Not I and Xho I was also ligated into pEG203 to yield plasmid ACB414. Constructs lacking the RING finger domain (amino acids 203 to 284) or the Ste5p homology domain (amino acids 440 to 531) were constructed by site-directed mutagenesis using the ExSite kit as recommended by the manufacturer (Stratagene); the introduced mutations were confirmed by sequencing. The fragments were cloned into pJC4-6 for two-hybrid analysis (generating plasmids pTP524 and ACB421) or PRD53 (generating plasmids pTP525 and pKP7) for mating assays. Genomic DNA isolated from strains IH2640 and IH2637 (5) was used to amplify the coding sequences of the far1-s alleles H7 and B4 by PCR using the primers oTP410 and oTP404. The obtained fragments were digested with Nco I and Xho I and ligated into pJG4-6 for two-hybrid analysis to generate plasmids ACB425 and ACB426. Expression of all Far1 mutants and fusion proteins was controlled by immunoblotting with Far1p-specific antibodies.
35. -6 M α factor to 3 ml of log phase cultures at 30°C. Cells were sonicated, fixed with formaldehyde to a final concentration of 3.7%, and viewed by differential interference microscopy. Yeast actin was visualized with rhodaminephalloidin (Molecular Probes, Eugene, OR) as described previously [M. Peter, A. M. Neiman, H.-O. Park, M. van Lohuizen, I. Herskowitz, EMBO J. 15, 7046 (1996)].
36. S. Henchoz et al., Genes Dev. 11, 3046 (1997).
37. M. Ziman et al., Mol. Biol. Cell 4, 1307 (1993); K. R. Ayscough et al., J. Cell Biol. 137, 399 (1997); J. R. Pringle et al., Cold Spring Harbor Symp. Quant. Biol. 60, 729 (1995).
38. M. Ziman et al., Mol. Biol. Cell 4, 1307 (1993); K. R. Ayscough et al., J. Cell Biol. 137, 399 (1997); J. R. Pringle et al., Cold Spring Harbor Symp. Quant. Biol. 60, 729 (1995).
39. M. Ziman et al., Mol. Biol. Cell 4, 1307 (1993); K. R. Ayscough et al., J. Cell Biol. 137, 399 (1997); J. R. Pringle et al., Cold Spring Harbor Symp. Quant. Biol. 60, 729 (1995).
40. 1-389-GFP expressed from the GAL promoter were present at similar levels in cells treated or not treated with α factor. GFP fluorescence was visualized on a Zeiss Axiovert 100 microscope equipped with a Chroma GFPII filter (excitation at 470 to 440 nm wavelength) and photographed with a Photometrics CCD (charge-coupled device) camera as described [M. Jaquenoud, M.-P. Gulli, K. Peter, M. Peter, EMBO J. 17, 5360 (1998)). Immunofluorescence experiments using Far1p fused to three copies of the myc epitope confirmed that, in the absence of pheromones, Far1p is localized in the nucleus, whereas in pheromone treated cells, Far1p is found predominantly in the cytosol.
41. 1-389-GFP expressed from the GAL promoter were present at similar levels in cells treated or not treated with α factor. GFP fluorescence was visualized on a Zeiss Axiovert 100 microscope equipped with a Chroma GFPII filter (excitation at 470 to 440 nm wavelength) and photographed with a Photometrics CCD (charge-coupled device) camera as described [M. Jaquenoud, M.-P. Gulli, K. Peter, M. Peter, EMBO J. 17, 5360 (1998)). Immunofluorescence experiments using Far1p fused to three copies of the myc epitope confirmed that, in the absence of pheromones, Far1p is localized in the nucleus, whereas in pheromone treated cells, Far1p is found predominantly in the cytosol.
42. M. Blondel and M. Peter, unpublished results.
43. K Y. Choi, B. Satterberg, D. M. Lyons, E. A. Elion, Cell 78, 499 (1994); S. Marcus, A. Polverino, M. Barr, M. Wigler, Proc. Natl. Acad. Sci. U.S.A. 91, 7762 (1994).
44. K Y. Choi, B. Satterberg, D. M. Lyons, E. A. Elion, Cell 78, 499 (1994); S. Marcus, A. Polverino, M. Barr, M. Wigler, Proc. Natl. Acad. Sci. U.S.A. 91, 7762 (1994).
45. J. A. Printen and G. F. Sprague Jr., Genetics 138, 609 (1994).
46. E. A. Elion, Trends Cell Biol. 5, 322 (1995); E. Leberer et al., Mol. Gen. Genet. 241, 241 (1993).
47. E. A. Elion, Trends Cell Biol. 5, 322 (1995); E. Leberer et al., Mol. Gen. Genet. 241, 241 (1993).
48. M. S. Whiteway et al., Science 269, 1572 (1995); C. Inouye, N. Dhillon, J. Thorner, ibid. 278, 103 (1997); Y. Feng, L. Y. Song, E. Kincaid, S. K. Mahanty, E. A. Elion, Curr. Biol. 8, 267 (1998); P. M. Pryciak and F. A. Huntress, Genes Dev. 12, 2684 (1998).
49. M. S. Whiteway et al., Science 269, 1572 (1995); C. Inouye, N. Dhillon, J. Thorner, ibid. 278, 103 (1997); Y. Feng, L. Y. Song, E. Kincaid, S. K. Mahanty, E. A. Elion, Curr. Biol. 8, 267 (1998); P. M. Pryciak and F. A. Huntress, Genes Dev. 12, 2684 (1998).
50. M. S. Whiteway et al., Science 269, 1572 (1995); C. Inouye, N. Dhillon, J. Thorner, ibid. 278, 103 (1997); Y. Feng, L. Y. Song, E. Kincaid, S. K. Mahanty, E. A. Elion, Curr. Biol. 8, 267 (1998); P. M. Pryciak and F. A. Huntress, Genes Dev. 12, 2684 (1998).
51. M. S. Whiteway et al., Science 269, 1572 (1995); C. Inouye, N. Dhillon, J. Thorner, ibid. 278, 103 (1997); Y. Feng, L. Y. Song, E. Kincaid, S. K. Mahanty, E. A. Elion, Curr. Biol. 8, 267 (1998); P. M. Pryciak and F. A. Huntress, Genes Dev. 12, 2684 (1998).
52. L. S. Huang and I. Herskowitz, unpublished results.
53. F. Chang and I. Herskowitz, Cell 63, 999 (1990); M. Peter, A. Gartner, J. Horecka, G. Ammerer, I. Herskowitz, ibid. 73, 747 (1993); M. Peter and I. Herskowitz, Science 265, 1228 (1994); A. Gartner et al., Mol. Cell Biol. 18, 3681 (1998).
54. F. Chang and I. Herskowitz, Cell 63, 999 (1990); M. Peter, A. Gartner, J. Horecka, G. Ammerer, I. Herskowitz, ibid. 73, 747 (1993); M. Peter and I. Herskowitz, Science 265, 1228 (1994); A. Gartner et al., Mol. Cell Biol. 18, 3681 (1998).
55. F. Chang and I. Herskowitz, Cell 63, 999 (1990); M. Peter, A. Gartner, J. Horecka, G. Ammerer, I. Herskowitz, ibid. 73, 747 (1993); M. Peter and I. Herskowitz, Science 265, 1228 (1994); A. Gartner et al., Mol. Cell Biol. 18, 3681 (1998).
56. F. Chang and I. Herskowitz, Cell 63, 999 (1990); M. Peter, A. Gartner, J. Horecka, G. Ammerer, I. Herskowitz, ibid. 73, 747 (1993); M. Peter and I. Herskowitz, Science 265, 1228 (1994); A. Gartner et al., Mol. Cell Biol. 18, 3681 (1998).
57. R. R. Zwaal et al., Cell 86, 619 (1996).
58. C. A. Parent, B. J. Blacklock, W. M. Froehlich, D. B. Murphy, P. N. Devreotes, ibid. 95, 81 (1998); S. G. Ward, K. Bacon, J. Westwick, Immunity 9, 1 (1998).
59. C. A. Parent, B. J. Blacklock, W. M. Froehlich, D. B. Murphy, P. N. Devreotes, ibid. 95, 81 (1998); S. G. Ward, K. Bacon, J. Westwick, Immunity 9, 1 (1998).
60. P. N. Adler, R. E. Krasnow, J. Liu, Curr. Biol. 7, 940 (1997); M. Gho, F. Schweisguth, Nature 393, 178 (1998); D. I. Strutt, U. Weber, M. Mlodzik, ibid. 387, 292 (1997).
61. P. N. Adler, R. E. Krasnow, J. Liu, Curr. Biol. 7, 940 (1997); M. Gho, F. Schweisguth, Nature 393, 178 (1998); D. I. Strutt, U. Weber, M. Mlodzik, ibid. 387, 292 (1997).
62. P. N. Adler, R. E. Krasnow, J. Liu, Curr. Biol. 7, 940 (1997); M. Gho, F. Schweisguth, Nature 393, 178 (1998); D. I. Strutt, U. Weber, M. Mlodzik, ibid. 387, 292 (1997).
63. J. Gyuris, E. Golemis, H. Chertkov, R. Brent, Cell 75, 791 (1993).
64. S. M. Hollenberg et al. Mol. Cell. Biol. 15, 3813 (1995).
65. R. Rothstein, Methods Enzymol. 194, 281 (1991).
66. N. Valtz and M. Peter, ibid. 283, 350 (1997).
67. E. Harlow and D. Lane, Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988).
68. 2-terminus of CDC24 using PCR, and the fragment was cloned into the vector p425(ADH) [D. Mumberg, R. Müller, M. Funk, Gene 156, 119 (1995)], which allows expression of Cdc24p from the constitutive ADH promoter. The plasmid fully restores viability of a temperature-sensitive cdcZ4-5 strain at 37°C.
69. 2-terminus of CDC24 using PCR, and the fragment was cloned into the vector p425(ADH) [D. Mumberg, R. Müller, M. Funk, Gene 156, 119 (1995)], which allows expression of Cdc24p from the constitutive ADH promoter. The plasmid fully restores viability of a temperature-sensitive cdcZ4-5 strain at 37°C.
70. A.-C. Butty and M. Peter, data not shown.
71. We thank members of each laboratory for helpful discussions; C. Boone, R. A. Arkowitz, J. Chant, D. Lew, M. Funk, E. Elion, E. O'Shea, H.-O. Park, E. Bi, and E. Leberer for plasmids and strains; B. Catarin for polyclonal antibodies to Far1p; and E. Leberer for antibodies to Bem1p. We also thank N. Valtz, S. Henchoz and K. Peter for help during early aspects of this work and J. Philips, V. Simanis, and R. Iggo for critical reading of the manuscript. L.S.H. was supported by an NIH postdoctoral fellowship. Work in the I.H. laboratory was supported by an NIH research grant (GM48052). P.M.P. is supported by grants from the Worcester Foundation, the Millipore Foundation, and NIH (GM57769). M.P. is supported by the Swiss National Science Foundation, the Swiss Cancer League, and a Helmut Horten Incentive award. I.H. dedicates this paper to J. Stahl.